CellSearch®, the only CTC system that has been cleared by the US Food and Drug Administration (FDA) for clinical use in patients with metastatic breast, colorectal and prostate cancer (20–22), utilizes anti-EpCAM (epithelial cell adhesion molecule) immunomagnetic beads to capture epithelial CTCs. This evidence concerns the gene EPCAM and prostate carcinoma.